William Blair analyst Matt Phipps has maintained their bullish stance on MRUS stock, giving a Buy rating today.
Matt Phipps has given his Buy rating due to a combination of factors including Merus’s promising clinical trial developments and strategic advancements. The company is making significant progress in its LiGeR-HN1 and LiGeR-HN2 trials, with expectations to achieve substantial enrollment by the end of 2025. This progress is complemented by the anticipated release of updated clinical data, which includes promising results from the petosemtamab and Keytruda combination in treating head and neck squamous cell carcinoma.
Moreover, Merus has recently secured a breakthrough therapy designation for petosemtamab in combination with Keytruda, highlighting the potential of their treatment approach. The initial results from this combination have shown a significant response rate, and the upcoming data is expected to confirm these findings with a larger patient cohort. These developments suggest a strong potential for Merus’s treatments to make a meaningful impact, justifying the Buy rating.
In another report released today, Needham also reiterated a Buy rating on the stock with a $83.00 price target.